We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Blood Test Could Diagnose Schizophrenia and Other Disorders

By LabMedica International staff writers
Posted on 22 Feb 2017
Schizophrenia is a chronic, severe mental disorder that affects approximately 1% of the adult population in the USA and influences how a person thinks, feels, and behaves. More...
The onset of symptoms usually begins between ages 16 and 30. Symptoms can range from visual and auditory hallucinations and movement disorders to difficulty beginning and sustaining activities.

The diagnosis of schizophrenia and similar disorders requires a thorough psychological evaluation and a comprehensive medical exam to rule out other conditions. A patient may be evaluated for six or more months before receiving a diagnosis and beginning treatment, particularly if he or she shows only early signs of the disorder.

Scientists at the University of Maryland have developed a blood test that could help doctors more quickly diagnose schizophrenia and other disorders. They used a discovery-driven approach based on the assumptions that chemical biomarkers relating to oxidative stress could be found in blood, and that they could be measured by common electrochemical instruments.

The team used performed an initial clinical evaluation using serum from 10 people diagnosed with schizophrenia, a mental health disorder that is increasingly linked to oxidative stress. The scientists used an iridium salt, potassium hexachloroiridate (K2IrCl6), to probe serum for reducing activities that can transfer electrons to iridium and thus generate detectable optical and electrochemical signals. They showed that this Ir-reducing assay can detect various biological reductants and is especially sensitive to glutathione (GSH) compared to alternative assays.

The new testing method was able to correctly differentiate the samples of those who had been diagnosed with schizophrenia from those who had no history of the disorder. Deana L. Kelly PharmD, BCPP, a professor of psychiatry and a co-author of study said, “Much emerging data suggests that schizophrenia and other psychiatric disorders may be due, in part, to inflammation and oxidative stress abnormalities. Current methods for measuring these potential biomarkers are not standardized and have many flaws.” The study was published on February 7, 2017, in the journal Analytical Chemistry.


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Platinum Member
Integrated Biochemical & Immunological System
Biolumi CX Solution X10+C10
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: 123RF

Genetic Testing Program Helps Uncover Inherited Risk in Pediatric Cancer

Inherited cancer risk can affect children, adolescents and young adults, but it may not always be apparent from tumor type or family history alone. Some cancer syndromes require specialized expertise and... Read more

Immunology

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Microbiology

view channel
Image: Each PhAST instrument supports random-access processing of up to four samples simultaneously, delivering a throughput of up to 12 samples per eight-hour shift. (Photo courtesy of PhAST)

FDA Clears Rapid Phenotypic Antimicrobial Susceptibility System for Positive Blood Cultures

Bloodstream infections require prompt treatment, but antimicrobial susceptibility results often lag behind a positive blood culture. Conventional testing can take another 24 to 48 hours after a culture... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.